Last reviewed · How we verify
NCT06040021
Distinct Metastatic Phenotypes Between Early-onset and Late-onset Colorectal Cancer
trial testing standardized treatment in Early-onset Colorectal Cancer in 15,244 participants. Completed in 30 June 2023.
31 December 2018
Quick facts
| Lead sponsor | Fudan University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 15,244 |
| Start date | 1 January 2008 |
| Primary completion | 31 December 2018 |
| Estimated completion | 30 June 2023 |
Drugs / interventions tested
- standardized treatment
Conditions studied
- Early-onset Colorectal Cancer — all drugs for Early-onset Colorectal Cancer →
- Late-onset Colorectal Cancer — all drugs for Late-onset Colorectal Cancer →
Sponsor
Fudan University
Who can join
Adults 16 to 95, any sex, with Early-onset Colorectal Cancer or Late-onset Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The clinical and pathological features of early-onset colorectal cancer (EOCRC) differ from those of late-onset colorectal cancer (LOCRC). Our research aims to thoroughly elucidate the distinctions between them by analyzing clinical prognosis, metastatic patterns, gene expression, and genomic mutation profiles. Our deliberation will uncover latent strategies for personalized therapeutic of both EOCRC and LOCRC.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06040021
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of standardized treatment
Trials testing the same drug.
- NCT04093336 — Effect of Mesenchymal Stem Cells(MSCs) Transplantation for Acute Cerebral Infarction Patients · Phase 1, PHASE2 · unknown
Other recruiting trials for Early-onset Colorectal Cancer
Currently open trials in the same condition.
- NCT06568679 — Earlier Detection and Optimization of Treatment and Prognosis for Patients With Early-onset Colorectal Cancer · recruiting
Other Fudan University trials
Trials by the same sponsor.
- NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
- NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
- NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
- NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
- NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06040021 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fudan University
- Last refreshed: 15 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06040021.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing